Engineered bone for probing organotypic growth and therapy response of prostate cancer tumoroids in vitro.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30682644.
- Also identified by DOI 10.1016/j.biomaterials.2019.01.027 and PMC identifier 7094882.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mechanistic analysis of metastatic prostate cancer (PCa) biology and therapy response critically depends upon clinically relevant three-dimensional (3D) bone-like, organotypic culture. We here combine an engineered bone-mimetic environment (BME) with longitudinal microscopy to test the growth and therapy response of 3D PCa tumoroids. Besides promoting both tumor-cell autonomous and microenvironment-dependent growth in PCa cell lines and patient-derived xenograft cells, the BME enables in vivo-like tumor cell response to therapy, and reveals bone stroma dependent resistance to chemotherapy and BME-targeted localization and induction of cytoxicity by Radium-223. The BME platform will allow the propagation, compound screening and mechanistic dissection of patient-derived bone tumor isolates and applications toward personalized medicine.
Medical subject headings
- Antineoplastic Agents
- Drug Screening Assays, Antitumor
- Prostatic Neoplasms